Azacitidine in a patient with newly diagnosed acute myeloid leukemia and poor risk cytogenetics: Outcomes of prolonged therapy

Leukemia Research

Volumn 36, Issue 4, 2012, Pages

  Pappa, Vasiliki ^a   Girkas, Konstantinos ^a   Sambani, Constantina ^b   Pagageorgiou, Sotiris ^c   Tsirigiotis, Panagiotis ^c   Karvounis, Kiki ^c   Stathopoulou, Evangelia ^c   Economopoulos, Theofanis ^c   Dimitriadis, George ^c   Dervenoulas, Ioannis ^c  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^c GENESIS Pharma SA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; HEMOGLOBIN;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; BLOOD TOXICITY; BONE MARROW BIOPSY; CANCER PATIENT; CASE REPORT; CAUCASIAN; CYTOGENETICS; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INJECTION SITE REACTION; KARYOTYPE 46,XX; KARYOTYPING; LABORATORY TEST; LETTER; LEUKOCYTE COUNT; LONG TERM CARE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPHIL COUNT; PATIENT REFERRAL; PRIORITY JOURNAL; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ABNORMAL KARYOTYPE; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID, ACUTE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; TREATMENT OUTCOME;

EID: 84857236217     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.11.022     Document Type: Letter

References (10)

1. Ferrara F., Annunziata M., Copia C., Magrin S., Mele G., Mirto S. Therapeutic options and treatment results for patients over 75 years of age with acute myeloid leukemia. Haematologica 1998, 83:126-131.
2. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology. Acute myeloid leukemia. V. 2.2010. accessed 01.06.10. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
3. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
4. Fenaux P., Mufti G.J., Hellström-Lindberg E., Santini V., Gattermann N., Germing U., et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010, 28:562-569.
5. Germing U., Gattermann N., Strupp C., Aivado M., Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 2000, 24:983-992.
6. Deschler B., de Witte T., Mertelsmann R., Lübbert M. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica 2006, 91:1513-1522.
7. Thépot S., Itzykson R., Seegers V., Recher C., Quesnel B., Delaunay J., et al. Azacytidine (AZA) as first line therapy in AML: results of the French ATU program. Blood 2009, 114:347. [abstract 843].
8. Cross M., Jaekel N., Krahl R., Junghanss C., Maschmeyer G., Tran T., et al. Low levels of global (LINE) and CDH13 methylation at diagnosis and rapid clearance of marrow blasts correlate with a better haematological response to azacitidine in patients with newly diagnosed and refractory/relapsed AML not eligible for or resistant to chemotherapy: a multi-centre phase I/II-study of the East German Haematology and Oncology Study Group (OSHO). Blood 2009, 114:1036. [abstract 2642].
9. Gardin C., Prébet T., Bouabdallah K., Caillot D., Guerci A., Raffoux E., et al. A phase II study of post-remission therapy with azacitidine (AZA) in patients with AML post-MDS and high-risk MDS: a GFM group study. Blood 2009, 114:348. [abstract 344].
10. Jabbour E., Giralt S., Kantarjian H., Garcia-Manero G., Jagasia M., Kebriaei P., et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 2009, 115:1899-1905.